Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

AstraZeneca completes acquisition of biotech company, EsoBiotec: Cambridge, UK Wednesday, May 21, 2025, 09:00 Hrs [IST] AstraZeneca announced the successful completion of the acqu ...

The acquisition, initially announced in March, sees AstraZeneca pay USD425 million up front, with an additional USD575 million in potential milestone payments, bringing the total consideration to up ...

AstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell ...

Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...

(Sharecast News) - London equities ended the week higher on Friday, supported by gains in pharmaceutical and energy stocks. The FTSE 100 index closed up 0.59% at 8,684.44 points, while the FTSE 250 ...

Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration ...

AstraZeneca, one of the world’s leading pharmaceutical brands, bought his company two weeks ago. Jean-Pierre Latere is his name, and his startup, EsoBiotec, was purchased by the British giant. Latere, ...

WILMINGTON, Del., May 19, 2025--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide ...

Q1 2025 Management View CEO Teresa Elder highlighted the company’s strong momentum in greenfield markets, achieving penetration rates above 16%, and adding 13,700 new homes passed during the quarter.

Apart from four billion-dollar deals valued at $1bn or more driven by large pharma, the industry remains cautious given the uncertainty surrounding US President Donald Trump’s as-yet-unspecified ...